GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Mesoblast Limited
Shares of Mesoblast, a cell therapy company, are highly volatile. Their price is driven not by financial performance, but by clinical trial results and regulatory decisions regarding its stem cell-based drugs, creating binary outcomes for investors.
Share prices of companies in the market segment - Stem_cells
Mesoblast is an Australian biotech company and a pioneer in stem cell therapy. We classify it as part of the Stem_cells sector, and the chart below reflects the dynamics of this industry, as well as the company's long and complex history of clinical trials.
Broad Market Index - GURU.Markets
Mesoblast is an Australian biotech company, a leader in regenerative medicine and stem cell-based cell therapy development. It is a component of the GURU.Markets index. The chart below shows the US market. See how Mesoblast shares compare to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
MESO - Daily change in the company's share price Mesoblast Limited
The daily price change of Mesoblast, a cell therapy company, reflects the extreme volatility of the biotech sector. change_co measures the reaction to regulatory decisions and clinical trial data. This metric is the basis for analyzing high-risk pharmaceutical assets on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Stem_cells
Mesoblast Limited is a biotech company. This chart highlights the sector's extreme volatility. Comparison with MESO, which focuses on cell therapy, helps assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Mesoblast is an Australian biotech company, a pioneer in stem cell therapy. This is one of the most cutting-edge and speculative areas in medicine. The chart below illustrates the extreme volatility typical of this sector, reflecting the enormous expectations and risks.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Mesoblast Limited
Mesoblast is an Australian biotech company and a pioneer in stem cell therapy. Its year-over-year performance has been extremely volatile, reflecting both successes and failures in clinical trials, typical of this high-risk strategy.
Annual dynamics of market capitalization of the market segment - Stem_cells
Mesoblast Limited is an Australian biotechnology company pioneering stem cell-based cell therapy. Its stock price is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the enormous potential and high risks of this cutting-edge field of medicine.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Mesoblast, an Australian cell therapy company, is a highly speculative stock. Its share price (ADR) is entirely dependent on clinical trial results and regulatory decisions. The chart bears no relation to economics, but rather reflects the binary outcomes of cutting-edge science.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Mesoblast Limited
Mesoblast, an Australian company and a pioneer in stem cell therapy, shows sharp monthly fluctuations reflecting clinical trial results and regulatory decisions regarding its drugs.
Monthly dynamics of market capitalization of the market segment - Stem_cells
This chart reflects the dynamics of the biotech sector, particularly in cell therapy. For Mesoblast, one of the veterans, it's the backdrop. Its volatile movements reflect its long and complex history of clinical trials and interactions with the FDA.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Mesoblast Limited is an Australian biotechnology company focused on cell therapy. Its shares are highly volatile, driven by clinical trial results and regulatory decisions. Mesoblast's performance is largely uncorrelated with the market, representing a bet on scientific success.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Mesoblast Limited
Mesoblast Limited is an Australian biotechnology company developing stem cell-based therapies. Its weekly stock price is highly volatile and depends on regulatory decisions, such as the FDA, regarding its drugs, which can lead to sharp ups and downs.
Weekly dynamics of market capitalization of the market segment - Stem_cells
Mesoblast, as a company working with cutting-edge stem cell technology, moves solely on the heels of regulatory announcements. Its performance is completely disconnected from the pharmaceutical sector. The chart clearly illustrates these sharp, non-market fluctuations caused by FDA rulings.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Mesoblast is an Australian cell therapy company. Its shares (ADR) are highly volatile and driven by news of clinical trials and regulatory decisions. The chart clearly demonstrates this disconnect from market trends.
Market capitalization of the company, segment and market as a whole
MESO - Market capitalization of the company Mesoblast Limited
The market capitalization of Mesoblast, an Australian biotech specializing in cell therapy, reflects the hopes and disappointments surrounding this cutting-edge field of medicine. Its volatile chart reflects investor reactions to regulatory decisions regarding its stem cell-based therapies. It's a high-risk bet on the future of regenerative medicine.
MESO - Share of the company's market capitalization Mesoblast Limited within the market segment - Stem_cells
Mesoblast Limited is a pioneer in stem cell-based cell therapy. Its market share and market capitalization reflect both the potential of its platform for treating inflammatory diseases and the high risks associated with biotech development.
Market capitalization of the market segment - Stem_cells
Here's a chart showing the biotech sector's market capitalization, and Mesoblast is a pioneer in stem cell therapy. The dynamics of this market are full of both hope and disappointment. Mesoblast's journey is a shining example of how difficult it is to bring a revolutionary technology to commercial success after enduring the rigors of clinical trials.
Market capitalization of all companies included in a broad market index - GURU.Markets
Mesoblast is an Australian biotech company, a pioneer in stem cell therapy. Its market capitalization reflects the promise and risks associated with this cutting-edge field of medicine. The chart below shows the economic weight of companies at the forefront of science.
Book value capitalization of the company, segment and market as a whole
MESO - Book value capitalization of the company Mesoblast Limited
Mesoblast's book value is derived from its intellectual property in mesenchymal stem cell technology and the capital it needs to conduct expensive clinical trials. This chart tells the story of one of the pioneers in cell therapy, whose book value is directly dependent on regulatory approvals and research results.
MESO - Share of the company's book capitalization Mesoblast Limited within the market segment - Stem_cells
Mesoblast is a leader in cell therapy development. The chart shows its share of actual R&D and manufacturing assets. These include its laboratories and sterile production facilities where stem cells are grown to treat complex diseases.
Market segment balance sheet capitalization - Stem_cells
Mesoblast Limited is a leader in cellular medicine. Its model is becoming increasingly capital-intensive, as the company has its own manufacturing facilities for its stem cell-based products. Compared to the biotech sector, this demonstrates its strategy of controlling the complex production process.
Book value of all companies included in the broad market index - GURU.Markets
Mesoblast's assets are not drugs, but a cutting-edge platform for developing stem cell-based therapies for the treatment of complex inflammatory diseases. The company's balance sheet reflects the value of its intellectual property and clinical developments. The chart shows the capital invested in this breakthrough area of regenerative medicine.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Mesoblast Limited
Mesoblast is an Australian biotech company focused on cell therapy. Its market value is based almost entirely on investor expectations for its clinical trials. Its book value is minimal. Its chart is a clear indicator of faith or skepticism in its scientific platform.
Market to book capitalization ratio in a market segment - Stem_cells
Mesoblast is a pioneer in stem cell therapy. Its market capitalization is a bet on regulatory approval of its drugs. This chart shows the classic biotech picture of a huge gap between investor expectations and the current book value.
Market to book capitalization ratio for the market as a whole
Mesoblast is a biotech company developing stem cell-based drugs. Its market capitalization is based almost entirely on investor faith in the potential of its scientific platform. The chart illustrates an extreme example, where the market valuation reflects hopes for a future breakthrough with minimal tangible assets.
Debts of the company, segment and market as a whole
MESO - Company debts Mesoblast Limited
Mesoblast is a biotech company pioneering stem cell-based cellular therapies. Advancing such revolutionary treatments through clinical trials requires significant and long-term funding. This chart shows how the company raises capital to support its cutting-edge research.
Market segment debts - Stem_cells
Mesoblast Limited is an Australian biotech company specializing in stem cell therapy. This is a cutting-edge but risky field, requiring significant funding for clinical trials. This chart shows how the company funds its expensive research and how its financial structure reflects its progress toward commercialization.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Mesoblast Limited
Mesoblast is an Australian biotech company pioneering cell therapy. This chart shows its financial position at the late-stage clinical trial stage. Its lack of debt and reliance on equity and partnerships is typical for companies whose future depends on regulatory approval of their innovative but risky products.
Market segment debt to market segment book capitalization - Stem_cells
Mesoblast is a biotech company specializing in developing cell therapies for the treatment of various diseases. This chart shows the debt burden in the innovative regenerative medicine sector. It helps understand how the company finances its expensive and time-consuming clinical trials compared to other players in this cutting-edge field.
Debt to book value of all companies in the market
Mesoblast, a cell therapy company, relies on research funding. The chart shows the overall debt burden for the entire economy. It emphasizes that for such companies, the overall credit climate is not as important as the availability of venture capital willing to finance long-term and risky research projects.
P/E of the company, segment and market as a whole
P/E - Mesoblast Limited
For Mesoblast, an Australian stem cell biotech, this chart reflects a long and difficult relationship with regulators. Investors' assessment of its potential profits depends heavily on their belief that its drugs will finally receive FDA approval. The trend reflects the regulatory announcements that determine the company's fate.
P/E of the market segment - Stem_cells
This chart reflects the average valuation for the speculative biotech sector—a benchmark for Mesoblast. Comparing this stem cell company's valuation to the industry average clearly demonstrates how investors assess the risks associated with its long history of regulatory interactions.
P/E of the market as a whole
Mesoblast is developing stem cell-based therapies for the treatment of complex inflammatory diseases. This is a cutting-edge but risky area of medicine. This graph of overall investor risk appetite in biotech is vital for Mesoblast. It determines whether investors are willing to fund expensive clinical trials with uncertain outcomes.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Mesoblast Limited
Mesoblast Limited is an Australian biotech company specializing in developing stem cell-based drugs for the treatment of inflammatory diseases. Its valuation is a bet on the approval of its drugs. This chart shows analysts' belief that its cell therapy will prove effective and receive regulatory approval.
%20P%2FE%20Mesoblast%20Limited&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Mesoblast-Limited&v=1772636099632 "Chart of the company's future (projected) P/E Mesoblast Limited")
Future (projected) P/E of the market segment - Stem_cells
Mesoblast is an Australian biotech company specializing in the development of stem cell-based therapies. Its valuation, relative to other biotechs, reflects the high risks and potentially huge returns of its platform. This demonstrates the level of confidence investors have in its ability to secure regulatory approval for its innovative treatments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Stem_cells&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Stem_cells&v=1772636099667 "Future (projected) P/E graph of the market segment - Stem_cells")
Future (projected) P/E of the market as a whole
Mesoblast is an Australian biotech company specializing in developing stem cell-based drugs for the treatment of inflammatory diseases. Its value is almost entirely dependent on the success of its clinical trials. This chart reflects the overall risk appetite of investors, which is critical for funding high-risk biotech companies.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772636099678 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Mesoblast Limited
Mesoblast is an Australian biotechnology company pioneering stem cell-based regenerative medicine. Its financial results, reflected here, are dependent on clinical trial results and regulatory approvals for its cell therapies for various diseases.
Profit of companies in the market segment - Stem_cells
Mesoblast Limited is an Australian biotechnology company pioneering stem cell-based regenerative medicine. This chart reflects the financial health of the cell therapy sector, demonstrating how close this cutting-edge field is to commercialization and achieving sustainable profitability.
Overall market profit
Mesoblast is an Australian biotech company specializing in cell therapy. Its future depends on the results of clinical trials and regulatory approvals, particularly from the FDA. It's a high-risk, high-potential company that operates according to the laws of science and medicine, not the economic cycles shown in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Mesoblast Limited
Mesoblast Limited is an Australian biotechnology company pioneering stem cell-based therapies. Its future profitability depends on regulatory approval for its drugs, particularly those for the treatment of graft-versus-host disease. This chart shows analysts' assessments of the company's chances of commercializing its innovative developments.
%20profit%20of%20the%20company%20Mesoblast%20Limited&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Mesoblast-Limited&v=1772636099793 "Graph of future (projected) profit of the company Mesoblast Limited")
Future (predicted) profit of companies in the market segment - Stem_cells
Mesoblast Limited is an Australian biotech company and a pioneer in stem cell-based regenerative medicine. Their drugs target complex inflammatory diseases. This chart shows the forecast for this segment. It illustrates the high risk, but also the enormous potential, of cell therapy if approved by regulators.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Stem_cells&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Stem_cells&v=1772636099798 "Graph of future (predicted) profits of companies in a market segment - Stem_cells")
Future (predicted) profit of the market as a whole
Mesoblast Limited is an Australian biotechnology company specializing in stem cell therapy. This projected profit curve impacts the availability of capital for the biotech sector. During periods of market optimism, investors are more willing to fund innovative and risky developments, which is critical for the advancement of Mesoblast's cell therapy.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772636099803 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Mesoblast Limited
Mesoblast is an Australian biotech company specializing in stem cell therapy. This figure reflects investor estimates of the potential revenue from its cell therapy, which is in various stages of clinical trials for the treatment of a range of diseases.
P/S market segment - Stem_cells
Mesoblast is an Australian biotech company and a global leader in stem cell-based regenerative medicine. This chart shows the average valuation in the cell therapy sector. It reflects investor expectations for the potential of Mesoblast's platform for treating complex inflammatory diseases and heart failure.
P/S of the market as a whole
Mesoblast Limited is an Australian biotechnology company developing stem cell-based therapies for the treatment of inflammatory diseases and heart failure. Future revenue is dependent on regulatory approval. This chart serves as a contrast, showing how the market values companies with breakthrough but not yet commercialized technologies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Mesoblast Limited
Mesoblast Limited is an Australian biotech company developing stem cell-based drugs. Its valuation depends almost entirely on the future success of its drugs in clinical trials. The chart shows how investors assess the risks and potential rewards of its innovative, but not yet widely proven, technology.
%20P%2FS%20Mesoblast%20Limited&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Mesoblast-Limited&v=1772636099885 "The graph of the company's future (projected) P/S Mesoblast Limited")
Future (projected) P/S of the market segment - Stem_cells
Mesoblast is an Australian biotech company and a global leader in stem cell-based regenerative medicine. Its products target severe inflammatory diseases. This chart shows how the market assesses the commercial potential of this cutting-edge cell therapy compared to other biotech companies.
%20P%2FS%20market%20segment%20graph%20-%20Stem_cells&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Stem_cells&v=1772636099914 "Future (projected) P/S market segment graph - Stem_cells")
Future (projected) P/S of the market as a whole
Market sentiment, as reflected in this chart, is important for biotech. For Mesoblast, a leader in cell therapy, it's an indicator of investors' risk appetite. Market optimism allows the company to raise capital for expensive clinical trials of its drugs aimed at treating complex inflammatory diseases.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772636099966 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Mesoblast Limited
Mesoblast is a regenerative medicine company developing mesenchymal stem cell-based therapeutics for the treatment of inflammatory diseases. This chart reflects revenue from royalties and licensing agreements. As new drugs are approved, it will show revenue from sales in cardiology and oncology.
Sales of companies in the market segment - Stem_cells
Mesoblast Limited is an Australian biotechnology company and a global leader in stem cell-based medicine. This chart illustrates the growth of the regenerative medicine sector. Mesoblast's platform enables the development of drugs for the treatment of complex inflammatory diseases, and its research has the potential to lead to breakthroughs in this cutting-edge field.
Overall market sales
Mesoblast Limited is an Australian biotechnology company specializing in stem cell therapy. Its market capitalization is dependent on clinical trial results. The overall economic climate, reflected in this chart, influences the investment climate in the biotechnology sector and investor willingness to fund cutting-edge research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Mesoblast Limited
Mesoblast is an Australian biotech company and a pioneer in stem cell therapy. Its developments are aimed at treating complex inflammatory diseases. The company's future success depends on regulatory approval of its cell-based therapies. This chart reflects analysts' confidence in the potential of regenerative medicine and Mesoblast's technology.
%20sales%20of%20the%20company%20Mesoblast%20Limited&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Mesoblast-Limited&v=1772636100196 "Schedule of future (projected) sales of the company Mesoblast Limited")
Future (projected) sales of companies in the market segment - Stem_cells
Mesoblast Limited is an Australian company developing stem cell-based therapies for the treatment of inflammatory diseases. This forecast highlights expectations for the cell therapy sector and reflects the potential of regenerative medicine, where Mesoblast is a pioneer seeking to commercialize its innovative developments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Stem_cells&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Stem_cells&v=1772636100198 "Schedule of future (projected) sales of companies in the market segment - Stem_cells")
Future (projected) sales of the market as a whole
Mesoblast Limited is an Australian biotechnology company, a global leader in stem cell-based regenerative medicine. Its market capitalization is dependent on clinical trial results. The overall economic environment, reflected in this chart, influences the availability of capital to fund expensive cell therapy research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772636100230 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Mesoblast Limited
Mesoblast is at the forefront of regenerative medicine, developing stem cell-based therapies. This chart shows the biotech company's financial performance during clinical trials. Negative values reflect significant investment in research, which, if successful, could lead to breakthrough treatments.
Market segment marginality - Stem_cells
Mesoblast Limited is an Australian biotechnology company and a global leader in stem cell-based regenerative medicine. Its financial performance reflects significant investment in clinical research. This chart provides an overview of Mesoblast's operating model compared to other companies in the advanced field of cell therapy.
Market marginality as a whole
Mesoblast is an Australian biotechnology company specializing in the development of stem cell-based therapies. This overall market profitability graph is irrelevant to the company. Mesoblast's future depends solely on the results of clinical trials, regulatory approval, and the ability to demonstrate the efficacy of its innovative platform for the treatment of complex diseases.
Employees in the company, segment and market as a whole
Number of employees in the company Mesoblast Limited
Mesoblast is an Australian biotechnology company pioneering mesenchymal stem cell-based cell therapy. The chart shows the scientific and clinical team. The dynamics of the team reflect the clinical trial phases and regulatory processes for its innovative products.
Share of the company's employees Mesoblast Limited within the market segment - Stem_cells
Mesoblast Limited is a pioneer in regenerative medicine, developing stem cell-based therapies. This chart shows the percentage of leading scientists and clinicians in this cutting-edge and niche field that the company attracts. It reflects its concentration of unique scientific expertise, essential for bringing fundamentally new treatments to market.
Number of employees in the market segment - Stem_cells
Mesoblast Limited is an Australian biotechnology company and a global leader in regenerative medicine using mesenchymal stem cells (MSCs). Its therapeutic products target severe inflammatory diseases. This chart reflects its involvement in the cutting-edge cell therapy sector, which promises to revolutionize the treatment of many complex diseases.
Number of employees in the market as a whole
Mesoblast is an Australian biotechnology company pioneering stem cell-based regenerative medicine. Their research is aimed at treating complex inflammatory diseases. This cutting-edge research creates unique opportunities for researchers. The success of such companies determines the future of medicine and the biotechnology sector.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Mesoblast Limited (MESO)
Mesoblast is an Australian biotech company specializing in cell therapy. This chart reflects investor confidence in regenerative medicine. Its very high market cap per employee suggests that the market is valuing its platform's potential to treat complex diseases, not current revenue or team size.
%20of%20the%20company%20Mesoblast%20Limited%20(MESO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Mesoblast-Limited-MESO&v=1772636100515 "Chart of market capitalization per employee (in thousands of dollars) of the company Mesoblast Limited (MESO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Stem_cells
Mesoblast (MESO) is an Australian biotech company specializing in developing stem cell therapies for severe inflammatory diseases. This chart shows the average market cap per employee in the sector. It helps assess how the market (following regulatory setbacks) values their technology platform per scientist.
%20by%20market%20segment%20-%20Stem_cells&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Stem_cells&v=1772636100548 "Market capitalization per employee (in thousands of dollars) by market segment - Stem_cells")
Market capitalization per employee (in thousands of dollars) for the overall market
Mesoblast Limited is an Australian company developing stem cell-based therapies. This chart shows the average market value of each employee's contribution, highlighting the high value the market places on the potential of revolutionary medical technologies.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772636100605 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Mesoblast Limited (MESO)
Mesoblast is an Australian biotech company working in cell therapy (stem cells). It has cutting-edge, yet highly complex, R&D capabilities. This chart shows the company's per-employee loss, reflecting how much the company invests in each scientist and physician to conduct expensive clinical trials.
%20Chart%20Mesoblast%20Limited%20(MESO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Mesoblast-Limited-MESO&v=1772636100618 "Company Profit Per Employee (in thousands of dollars) Chart Mesoblast Limited (MESO)")
Profit per employee (in thousands of dollars) in the market segment - Stem_cells
Mesoblast (MESO) is a biotech R&D company (stem cells). This chart shows the benchmark for "Stem Cells" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the "burning" of money in the hopes of one or two mega-successes. The entire sector is an R&D race, spending billions on elite scientists.
%20in%20the%20market%20segment%20-%20Stem_cells&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Stem_cells&v=1772636100649 "Chart of profit per employee (in thousands of dollars) in the market segment - Stem_cells")
Profit per employee (in thousands of dollars) for the market as a whole
Mesoblast is an Australian biotech company specializing in cell therapy (stem cells) for the treatment of inflammatory diseases. It's an R&D company that has failed to receive FDA approval several times. This chart shows the high cost per employee—the "cost" of years of trying to commercialize their technology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772636100731 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Mesoblast Limited (MESO)
Mesoblast is a company developing stem cell-based drugs. For a biotech company at the forefront of science, this graph reflects the path to commercialization. It shows the potential for the approval of a single drug to lead to explosive growth in revenue per scientist or employee.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Mesoblast-Limited-MESO&v=1772636100808 "Sales chart per company employee Mesoblast Limited (MESO)")
Sales per employee in the market segment - Stem_cells
Mesoblast is a biotech company working in the field of regenerative medicine using stem cells. The company is in late-stage R&D. This chart shows the average revenue per employee in this segment. It serves as a productivity benchmark for commercial pharmaceutical companies and helps evaluate the effectiveness of Mesoblast's scientific team.
Sales per employee for the market as a whole
Mesoblast is a biotech company developing stem cell-based therapies. The company is in the clinical stage and has a complicated history with regulators. It has no stable commercial revenue. This metric is irrelevant. The real value lies in the potential of its R&D team to secure approval for its cell products.
Short shares by company, segment and market as a whole
Shares shorted by company Mesoblast Limited (MESO)
Mesoblast is an Australian stem cell biotech company. Its key drug has been rejected by the FDA several times. This chart illustrates the high level of skepticism among investors who don't believe Mesoblast will ever receive regulatory approval after so many setbacks and view the technology as questionable.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Mesoblast-Limited-MESO&v=1772636100859 "Short Shares Chart for the Company Mesoblast Limited (MESO)")
Shares shorted by market segment - Stem_cells
Mesoblast Limited is an Australian biotech company developing mesenchymal stem cell (MSC)-based therapies for the treatment of inflammatory diseases and heart failure. This chart reflects the total short position in the cell therapy sector. High values indicate general investor skepticism regarding the safety, efficacy, or commercialization of these complex treatments.
Shares shorted by the overall market
Mesoblast (MESO) is a clinical-stage biotech (stem cells). It's a highly speculative, money-burning industry. This indicator (`Short_All`) mirrors market fear. When it rises, it signals risk aversion. This pessimism, visible on the chart, is toxic for MESO, depriving it of access to capital for R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Mesoblast Limited (MESO)
Mesoblast is an Australian biotech company, a pioneer in stem cell therapy. It's a highly speculative field, full of both hope and disappointment. This chart measures the strength of these emotions. It shows when the stock is "overbought" on anticipation of FDA approval or "oversold" to the bottom after yet another regulatory rejection, reflecting the binary nature of biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Mesoblast-Limited-MESO&v=1772636100913 "RSI 14 indicator chart for the company's stock Mesoblast Limited (MESO)")
RSI 14 Market Segment - Stem_cells
Mesoblast is an Australian biotech company pioneering mesenchymal stem cell (MSC)-based cell therapy for inflammatory diseases. This chart reflects the overall sentiment in the biotech sector. It helps assess how the market views this speculative industry as a whole, and how Mesoblast stacks up against that backdrop.
RSI 14 for the overall market
Mesoblast (MESO), a stem cell company, is a company whose lifeline is this chart. Its business is pure R&D. During periods of euphoria, investors are willing to fund the "future of medicine." In moments of panic, they flee unprofitable biotech companies, and MESO risks running out of funds for its breakthrough but expensive research.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MESO (Mesoblast Limited)
Mesoblast (MESO) is a biotech company developing allogeneic (donor) stem cell-based therapies for inflammatory diseases. This chart shows the average price target, which reflects analysts' opinions on the high probability of success (or failure) in clinical trials and FDA approval.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MESO-Mesoblast-Limited&v=1772636101073 "A chart showing analyst consensus forecasts for the expected stock price. MESO (Mesoblast Limited)")
The difference between the consensus estimate and the actual stock price MESO (Mesoblast Limited)
Mesoblast is an Australian biotech venture capital firm developing a stem cell-based therapy (remestemcel-L) for inflammatory diseases. This chart shows the difference between the consensus estimate and the price, reflecting analysts' confidence in this high-risk R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MESO-Mesoblast-Limited&v=1772636101111 "A chart showing the difference between the consensus forecast and the actual stock price. MESO (Mesoblast Limited)")
Analyst consensus forecast for stock prices by market segment - Stem_cells
Mesoblast is an Australian biotech company developing mesenchymal stem cell-based therapies for the treatment of inflammatory diseases. This chart shows overall expectations for the stem cell sector. It reflects whether experts believe the company can achieve FDA approval after past setbacks.
Analysts' consensus forecast for the overall market share price
Mesoblast Limited is an Australian biotechnology company specializing in the development of stem cell-based therapies for the treatment of severe inflammatory diseases. This chart shows the overall risk appetite. For Mesoblast, a high-risk company dependent on regulatory decisions, overall market optimism is critical to raising capital for continued research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Mesoblast Limited
Mesoblast is an Australian biotech company, a global pioneer in stem cell therapy (allogeneic cell therapy). Their platform targets complex inflammatory diseases. This chart reflects their long and arduous R&D journey. It is highly volatile and reflects investor expectations for regulatory decisions (e.g., the FDA) on their key drugs.
AKIMA Market Segment Index - Stem_cells
Mesoblast (MESO) is an Australian biotech pioneer in cell therapy, developing stem cell-based therapies (MSCs) for the treatment of inflammation and heart disease. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does MESO's futuristic (stem cell) R&D platform differentiate it from the average pharma company?
The AKIM Index for the overall market
Mesoblast is an Australian biotech company developing allogeneic cell-based therapies for inflammatory diseases. It's a high-risk scientific bet. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative story, driven by regulatory decisions, compares to overall economic trends.
